SELECT PUBLICATIONS

The ATAC Trialists’ Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7(8):633-43. Abstract

Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract

Duffy S et al. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: First results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2005;21(2):545-53. Abstract

Fallowfield L et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004;22(21):4261-71. Abstract

Locker GY et al. The time course of bone fractures observed in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. Proc ASCO 2003;Abstract 98.

Thürlimann B et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353(26):2747-57. Abstract

 

 

 

 

 

 

 

 

 

 

 

Table of Contents

Top of Page

Home · Search

Editor:
Neil Love, MD

Interviews
Rache M Simmons, MD
- Select publications

Peter M Ravdin, MD, PhD
- Select publications

Henry M Kuerer, MD, PhD
- Select publications

Debu Tripathy, MD
- Select publications

D Lawrence Wickerham, MD
- Select publications

Richard Sainsbury, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office